Mylan N.V. (MYL) Price Target Raised to $39.00
A number of other research analysts have also issued reports on MYL. Cowen and Company reiterated a hold rating and issued a $30.00 target price (down from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on Mylan N.V. and gave the company a hold rating in a report on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on Mylan N.V. and gave the company a hold rating in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a sector perform rating and issued a $32.00 target price (down from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Finally, BMO Capital Markets reiterated an outperform rating and issued a $45.00 target price (down from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $41.99.
Shares of Mylan N.V. (MYL) opened at 38.29 on Friday. The stock has a market capitalization of $20.53 billion, a PE ratio of 30.95 and a beta of 1.30. The company’s 50 day moving average price is $32.08 and its 200-day moving average price is $36.45. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87.
Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the business posted $1.16 earnings per share. Equities research analysts predict that Mylan N.V. will post $4.57 EPS for the current year.
Institutional investors have recently bought and sold shares of the company. Global X Management Co. LLC increased its position in Mylan N.V. by 91.6% in the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after acquiring an additional 1,441 shares during the period. TLP Group LLC acquired a new position in Mylan N.V. in the 1st quarter valued at about $200,000. Doliver Capital Advisors LP acquired a new position in Mylan N.V. in the 2nd quarter valued at about $201,000. Eagle Global Advisors LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $205,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Mylan N.V. in the 2nd quarter valued at about $210,000. 71.97% of the stock is owned by institutional investors and hedge funds.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.